Skip to content
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

TFA Therapeutics, Inc. RAJAF

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.2M
▼ 0.6% YoY
$-154,822

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company specializes in cultivating Chinese rare medicinal herb, Cattle camphor mushroom raw material and sell of its finished products. As a result of the September Transaction, the Company spin off its then subsidiaries, Cordyceps Sunshine HK and Chengdu Skyherb, and thus the Cordyceps business has been ceased. For the year ended December 31, 2025, we generated revenue of $1,245,348 entirely from the sale of Cattle camphor mushroom products. Taiwanofungus Oral pill is a pill-form dietary supplement.

Written from the business description in Cordyceps Sunshine Biotech Holdings Co., Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 15 May 2026. Every sentence was checked against that document before publication.

Growth

USD 1.2M
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.2 · Net income -0.2
0.5M1.0M-0.3M-0.6M
202120242025
Compound annual growth
+185.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−12 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -11.3% · Net -12.4%
-500%-1000%
202120232025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin61.1%
Operating margin-11.3%
Net margin-12.4%
EBITDAUSD -5,885.00

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $
FY2024 · FCF -37231.0
-200000-400000
202120232025

Total assetsUSD 4.7M
EquityUSD -534,551.00
CashUSD 3,199.00
Current ratio0.19×

Equity funds -11% of total assets.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RAJAF, 5-year financial record
Metric 20252024202320222021
Revenue $B0.00.00.00.00.0
Operating income $B−0.0−0.00.0−0.0−0.0
EBITDA $B−0.00.00.0−0.0−0.0
Income tax $B◌0.00.00.00.0
Net income $B−0.0−0.00.0−0.0−0.0
Free cash flow $B◌−0.00.0−0.0−0.0
EPS, diluted $0.000.000.01−0.01−4.91
Dividend / sh $◌◌◌◌◌
Payout % — not applicable: no dividend—————
ROE % — not applicable: negative equity—————
Shares out B0.110.110.110.110.11

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 5 of the 5 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 14 checks were skipped: EPS is not tagged before 2021. 14 checks were skipped: revenue is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image